How Samsung Bioepis Is Laying A Path For Ophthalmic Biosimilars
Strategy Head Josh Lee Also Emphasizes Need For Biosimilar Education And Incentives
With the first approved rival to Lucentis in both the EU and US, Samsung Bioepis is laying the groundwork for biosimilars to break into ophthalmology ahead of launching its Byooviz version of ranibizumab, explains vice-president of commercial strategy Josh Lee.
